Akebia Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akebia Therapeutics, Inc. (AKBA) on December 22, 2022. The filing discloses two material definitive agreements entered into on the same date: an exclusive license agreement with Averoa SAS and a termination and settlement agreement with BioVectra Inc.
Key Financial Metrics and Agreements
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period. Instead, it details specific financial obligations and potential revenue streams arising from the new agreements:
- Averoa License Agreement: Akebia granted Averoa an exclusive license to develop and commercialize ferric citrate (Auryxia) in the European Economic Area, Turkey, Switzerland, and the UK. Akebia is entitled to tiered, escalating royalties ranging from a mid-single digit to a low double-digit percentage of net sales, subject to minimum royalty amounts in certain years.
- BioVectra Termination Settlement: Akebia agreed to pay BioVectra a total of $32,500,000 to terminate existing manufacture and supply agreements for ferric citrate drug substance. The payment structure includes an upfront payment of $17,500,000 and six quarterly payments of $2,500,000 commencing in April 2024.
Material Changes and Strategic Shifts
The filing represents a significant strategic shift in Akebia's commercial and supply chain operations for its proprietary product, Auryxia:
- Commercial Expansion: The company has outsourced commercialization of Auryxia in key European markets to Averoa, transitioning from a direct sales model (if applicable) or prior arrangements to a royalty-based partnership.
- Supply Chain Restructuring: The termination of agreements with BioVectra ends the company's obligation to purchase minimum quantities of drug substance at predetermined prices and reimburses costs for facility construction. This removes future fixed supply costs but incurs an immediate settlement liability.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreements. Key risks and contingencies include:
- Regulatory Risk: Averoa has the right to terminate the license agreement with 30 days' notice if the European Medicines Agency (EMA) rejects the marketing authorization application (MAA) and the parties agree a new application would not succeed.
- Termination Rights: Averoa may terminate the agreement for convenience with 12 months' notice after the first year. Akebia may terminate the associated supply agreement for convenience with 24 months' notice after January 1, 2024.
- Liquidity Impact: The company faces an immediate cash outflow of $17.5 million and future quarterly obligations totaling $15 million related to the BioVectra settlement.
Investor Verification Checklist
- Verify the impact of the $17.5 million upfront payment on the company's current cash position and liquidity runway.
- Review the specific terms of the "minimum royalty amounts" in the Averoa agreement to understand guaranteed revenue floors.
- Confirm the status of the EMA marketing authorization application for ferric citrate in the licensed territories.
- Assess the timeline for transitioning supply of ferric citrate from BioVectra to the new supply arrangement with Averoa.
- Monitor the filing of the full License and Termination agreements as exhibits to the upcoming Form 10-K for the year ending December 31, 2022.